Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. (ABIDO)
Abiraterone Acetate Maintenance in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. Randomized Phase II Study.
Sponsor: Apices Soluciones S.L.
Listed as NCT02036060, this PHASE2 trial focuses on Metastatic Prostate Cancer and remains completed. Sponsored by Apices Soluciones S.L., it has been updated 12 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Apr 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE2
-
Oct 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Oct 2019 [monthly]
Active Not Recruiting PHASE2
-
Nov 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Apices Soluciones S.L.
- Janssen, LP
- Spanish Oncology Genito-Urinary Group
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Badalona, Spain , Barcelona, Spain , Castellon, Spain , Córdoba, Spain , Guadalajara, Spain , Madrid, Spain , Málaga, Spain , Oviedo, Spain , Palma de Mallorca, Spain , Seville, Spain and 3 more locations